Beam Therapeutics Inc.

NASDAQ:BEAM

25.51 (USD) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q1
Revenue 11.7727.41316.19217.19320.11624.20820.03715.79916.6528.43251.0690.7630.0060.0060.0060.0060.0060.0060.0060.0060.00600000
Cost of Revenue 5.5765.4315.3627.4757.2917.0016.1875.6165.5155.2595.01854.62345.577190.10638.02827.82619.35421.54919.13111.36811.2128.6728.8496.1276.5026.502
Gross Profit 6.1961.979310.839.71812.82517.20713.8510.18311.1373.17346.051-53.86-45.571-190.1-38.022-27.82-19.348-21.543-19.125-11.362-11.206-8.672-8.849-6.127-6.502-6.502
Gross Profit Ratio 0.5260.2670.9830.5650.6380.7110.6910.6450.6690.3760.902-70.59-7,595.167-31,683.333-6,337-4,636.667-3,224.667-3,590.5-3,187.5-1,893.667-1,867.66700000
Reseach & Development Expenses 87.04184.818140.077100.0597.60899.64686.34185.28774.55665.4196.78154.62345.577190.10632.45129.82519.35421.54920.21712.54312.689.1799.8529.8547.0847.084
General & Administrative Expenses 29.62626.72443.25725.4124.65623.4922.68121.81524.06219.24717.77215.77413.40310.2738.3547.5026.9376.8126.165.4874.9773.9293.7112.8342.6622.662
Selling & Marketing Expenses -5.576-5.431-5.36200000000000000000000000
SG&A 24.0521.29337.89525.4124.65623.4922.68121.81524.06219.24717.77215.77413.40310.2738.3547.5026.9376.8126.165.4874.9773.9293.7112.8342.6622.662
Other Expenses 0000000000000-0.3050000-0.064-0.00200-5.648-4.00400
Operating Expenses 111.091106.111177.972125.46122.264123.136109.022107.10298.61884.657114.55370.39758.98200.37940.80537.32726.29128.36126.37718.0317.65713.10813.56312.6883.6953.695
Operating Income -104.895-104.132132.858-108.267-102.148-98.928-88.985-91.303-81.966-76.225-63.484-69.634-58.974-200.373-40.799-37.321-26.285-28.355-26.371-18.024-17.651-13.108-13.563-12.688-9.745-9.745
Operating Income Ratio -8.911-14.0530.42-6.297-5.078-4.087-4.441-5.779-4.922-9.04-1.243-91.263-9,829-33,395.5-6,799.833-6,220.167-4,380.833-4,725.833-4,395.167-3,004-2,941.83300000
Total Other Income Expenses Net 13.8835.46311.305-0.5197.4192.46851.636-15.86210.0167.011-1.22341.507-17.227-2.205-54.72.7-8.7-2.7-1.864-1.6-1-1-11.848-58.538-0.452-0.452
Income Before Tax -91.012-98.669144.163-96.088-82.776-96.46-37.349-107.165-71.95-69.214-64.707-28.118-76.253-201.56-95.464-34.452-34.218-30.458-27.85-19.005-17.861-13.61-25.194-71.151-10.197-10.197
Income Before Tax Ratio -7.731-13.3160.456-5.589-4.115-3.985-1.864-6.783-4.321-8.208-1.267-36.852-12,708.833-33,593.333-15,910.667-5,742-5,703-5,076.333-4,641.667-3,167.5-2,976.83300000
Income Tax Expense 0.0395.3881.366-17.366-24.188-12.42912.41-23.45-14.022-0.134-41.51617.2790.88254.665-4.0877.9332.1030.0550.9810.210.50265.349-6.2580.1120.112
Net Income -91.051-98.669142.797-96.088-82.776-84.031-38.349-109.575-48.5-55.192-64.573-28.118-76.253-201.56-95.464-34.452-34.218-30.458-27.85-19.005-17.861-13.61-25.194-69.8-10.309-10.309
Net Income Ratio -7.735-13.3160.452-5.589-4.115-3.471-1.914-6.936-2.913-6.546-1.264-36.852-12,708.833-33,593.333-15,910.667-5,742-5,703-5,076.333-4,641.667-3,167.5-2,976.83300000
EPS -1.11-1.211.77-1.22-1.08-1.16-0.54-1.56-0.69-0.8-0.95-0.42-1.23-3.35-1.59-0.69-0.69-0.99-0.91-0.54-0.51-0.39-0.72-1.99-8.11-8.11
EPS Diluted -1.11-1.211.73-1.22-1.08-1.16-0.54-1.56-0.69-0.8-0.95-0.42-1.23-3.35-1.59-0.69-0.69-0.99-0.91-0.54-0.51-0.39-0.72-1.99-8.11-8.11
EBITDA -99.319-98.701138.22-107.748-109.567-91.435-133.01-95.959-89.922-79.28-62.207-109.391-40.078-197.07515.173-40.021-16.44-24.555-24.929-15.516-15.793-11.37352.536-17.456-9.719-9.719
EBITDA Ratio -8.437-13.320.437-6.267-5.447-3.777-6.638-6.074-5.4-9.402-1.218-143.37-6,679.667-32,845.8332,528.833-6,670.167-2,740-4,092.5-4,154.833-2,586-2,632.16700000